Recently, several small-molecule inhibitors targeting methyltransferase-like 3 or fat mass and obesity-associated protein have been developed to modulate N 6 -methyladenosine modification, providing new opportunities for disease intervention, with the targeting of N6-methyladenosine-related pathways emerging as a promising therapeutic strategy. The gene discussed is METTL3; the disease is obesity due to melanocortin 4 receptor deficiency.